RT Journal Article
SR Electronic
T1 When we move cancer drugs from the second or third to the first line of treatment: what lessons can we learn from KEYNOTE-177 and JAVELIN-100
JF BMJ Evidence-Based Medicine
JO BMJ EBM
FD BMJ Publishing Group Ltd
SP bmjebm-2021-111702
DO 10.1136/bmjebm-2021-111702
A1 Myung S Kim
A1 Vinay Prasad
YR 2021
UL http://ebm.bmj.com/content/early/2021/06/03/bmjebm-2021-111702.abstract
AB